An advisory panel for the US Food and Drug Administration rejected a proposal from Pfizer and BioNTech on Friday to allow a third dose — or “booster” shot — of their COVID-19 vaccine for people ages 16 and above six months after a second shot, citing a lack of sufficient data on the safety and efficacy of the measure.
The panel may, however, consider extra vaccine doses for limited age groups, according to reports. Follow along here for all of the latest from Friday’s FDA panel.
US health officials had pushed back in recent weeks against the Biden administration’s plan to roll out booster shots on Monday, according to reports.
The White House said it will follow FDA guidance on extra COVID-19 dosess.
